Background
• CD4 and viral loads are used in clinical trials as surrogate endpoints for assessing efficacy of newly surrogate endpoints for assessing efficacy of newly available antiretrovirals (ARVs)
• ARVs may also act through other pathways or negatively affect the risk of disease
• This would not be identified prior to licensing Methods (events)
• For specific regimens used, Poisson regression was used to compare overall events:
• AIDS, non-AIDS events or death
• AIDS events (fatal and non-fatal) AIDS events (fatal and non fatal)
• non-AIDS events (fatal or non-fatal)
• malignancies, hepatic encephalopathy (grade 3-4), pancreatitis, cardiovascular events and end stage renal disease 1 renal disease 
Summary
• There was little evidence of substantial differences between ARVs in the incidence of fatal and non-fatal AIDS and non-AIDS events for a given CD4 or viral load
• Evidence that cART regimens which are licensed on the basis of changes in surrogate markers have similar risks of AIDS and non-AIDS events for a given CD4 and risks of AIDS and non AIDS events for a given CD4 and pVL
• This suggests there are unlikely to be major unidentified adverse effects of specific ARVs
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• Some evidence that a NRTI regimen including ABC, or ABC or unboosted ATV as third drugs, had higher overall event rates for a given CD4 or viral load
• ABC plus one other NRTI or ATV or ABC as third drugs p us o ot o o as t ugs had a higher incidence of non-AIDS events, particularly cardiovascular events
• Larger studies are required to investigate the small differences found
